Brokerages expect that Genocea Biosciences Inc (NASDAQ:GNCA) will report earnings per share (EPS) of ($0.20) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Genocea Biosciences’ earnings. Genocea Biosciences posted earnings per share of ($0.48) during the same quarter last year, which would indicate a positive year over year growth rate of 58.3%. The company is expected to report its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Genocea Biosciences will report full year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($0.80) to ($0.74). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.81) per share, with EPS estimates ranging from ($0.86) to ($0.75). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last posted its earnings results on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.03.
Shares of Genocea Biosciences (NASDAQ GNCA) opened at $1.00 on Tuesday. The stock has a market capitalization of $82.07, a price-to-earnings ratio of -0.51 and a beta of 1.55. Genocea Biosciences has a 12-month low of $0.79 and a 12-month high of $7.29. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51.
Several institutional investors have recently added to or reduced their stakes in GNCA. GSA Capital Partners LLP bought a new position in shares of Genocea Biosciences in the second quarter worth $100,000. Ameriprise Financial Inc. increased its holdings in shares of Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 2,300 shares during the period. Millennium Management LLC bought a new position in shares of Genocea Biosciences in the fourth quarter worth $145,000. New York State Common Retirement Fund bought a new position in shares of Genocea Biosciences in the second quarter worth $159,000. Finally, OxFORD Asset Management LLP bought a new position in shares of Genocea Biosciences in the second quarter worth $204,000. 10.10% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://stocknewstimes.com/2018/03/14/genocea-biosciences-inc-gnca-expected-to-announce-earnings-of-0-20-per-share.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.